Oppenheimer Maintains Outperform on Spruce Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Spruce Biosciences (NASDAQ:SPRB) but lowers the price target from $4 to $3.
June 13, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer's analyst Hartaj Singh maintains an Outperform rating on Spruce Biosciences but lowers the price target from $4 to $3, indicating a cautious optimism.
The maintained Outperform rating suggests continued confidence in the company's prospects, but the lowered price target reflects a more conservative outlook on its near-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100